Phase II Study of Everolimus Beyond Progression

Overview

This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement (recurred) on everolimus and exemestane hormone therapy. Everolimus is a chemotherapy drug that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen and progesterone are hormones that can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by lowering the amount of estrogen and progesterone the body makes. Giving everolimus with a different type of hormone therapy may be an effective treatment for breast cancer in patients who progressed on everolimus with exemestane.

Full Title of Study: “Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2020

Detailed Description

PRIMARY OBJECTIVE:

Progression free survival in patients with advanced or metastatic breast cancer receiving everolimus plus hormonal therapy beyond first progression.

SECONDARY OBJECTIVES:

1. Clinical benefit rate (sum of stable disease, partial response, complete response).

2. Response rate (partial response and complete response).

3. Overall survival.

4. Safety, side effects and tolerability profile of everolimus.

OUTLINE:

Patients receive everolimus orally (PO) daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant intramuscularly [IM] or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO 4 times daily [QID]; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.

Interventions

  • Drug: everolimus
    • Given PO
  • Drug: anastrozole
    • Given PO
  • Drug: letrozole
    • Given PO
  • Drug: tamoxifen citrate
    • Given PO
  • Drug: fulvestrant
    • Given IM or PO
  • Drug: megestrol acetate
    • Given PO

Arms, Groups and Cohorts

  • Experimental: Treatment (everolimus, hormone therapy)
    • Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.

Clinical Trial Outcome Measures

Primary Measures

  • Response rate (partial response plus complete response) using RECIST
    • Time Frame: Up to 2 years
    • Measured at different time points, e.g. 8, 16, and 24 weeks, and will be summarized as percentage of stable disease, complete remission or partial remission along with 95% confidence interval.
  • Progression-free survival (PFS)
    • Time Frame: Up to 2 years
    • The median PFS and survival rate at different time points for this study will be estimated by Kaplan-Meier method along with 95% confidence interval.

Secondary Measures

  • Clinical benefit rate (response rate plus stable disease)
    • Time Frame: Up to 2 years
    • Measured at different time points and summarized as a percentage along with 95% confidence interval.
  • Overall survival (OS)
    • Time Frame: From the initiation of alternate hormonal treatment in combination with everolimus to time of death from any cause, assessed up to 2 years
    • The median OS and survival rate at different time points for this study will be estimated by Kaplan-Meier method along with 95% confidence interval.
  • Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events version 4.0
    • Time Frame: Up to 2 years

Participating in This Clinical Trial

Inclusion Criteria

  • Estrogen (ER) and/or progesterone (PR)-positive at primary diagnosis and at metastatic diagnosis where tissue is available (defined as > or = 1% of staining nuclei)
  • Progressive or recurrent breast cancer defined as disease progression or recurrence while on a combination of exemestane with everolimus
  • Human epidermal growth factor receptor 2 (HER2)/neu-negative breast cancer by standard criteria (immunohistochemistry [IHC] < 3+ or fluorescence in situ hybridization [FISH] negative if IHC 2+) at primary diagnosis
  • Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion; if applicable, Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
  • Life expectancy > 6 months
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Absolute neutrophil count (ANC) > 1,500/µL
  • Platelets ≥ 100,000/µL
  • Hemoglobin > 10 g/dL
  • Creatinine ≤ 1.5 x upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 x ULN
  • International normalized ratio ≤ 1.3 (or ≤ 3 on anticoagulants)
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary disease
  • Signed informed consent
  • Adequate birth control
  • Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN; NOTE: in case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication

Exclusion Criteria

  • Prior treatment with everolimus other than in combination with hormonal therapy for treatment of breast cancer or prior treatment with another mammalian target of rapamycin (mTOR) inhibitor (sirolimus, temsirolimus) for any indication
  • HER2 positive disease as defined by 3+ IHC or positive FISH (both in primary and metastatic sites)
  • Active infection: temperature > 100 Fahrenheit (F), fever of unknown origin, active symptoms or signs of infection as defined by the investigator
  • Uncontrolled central nervous system metastases
  • Life-threatening, visceral metastases
  • Pregnant or lactating women
  • Prior chemotherapy within the last 4 weeks
  • Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation)
  • Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias
  • Hypersensitivity to trial medications (everolimus)
  • Emotional limitations, which the investigator judges could limit the patient's ability to follow up and comply with study procedures
  • Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
  • Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN
  • Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
  • A known history of human immunodeficiency virus (HIV) seropositivity
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of EVEROLIMUS (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
  • Patients with an active, bleeding diathesis
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVEROLIMUS)
  • Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest
  • Taking any of the following agents:
  • Chronic treatment with systemic steroids or another immunosuppressive agent (use of steroids as part of management of everolimus toxicities will be allowed)
  • Live vaccines
  • Patients who have received live attenuated vaccines within 1 week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guérin (BCG), yellow fever, varicella and TY21a typhoid vaccines
  • Drugs or substances known to be inhibitors or inducers of the isoenzyme cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A)

Gender Eligibility: Female

Minimum Age: 19 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Emory University
  • Collaborator
    • Novartis
  • Provider of Information About this Clinical Study
    • Principal Investigator: Elisavet Paplomata, Principal Investigator – Emory University
  • Overall Official(s)
    • Elisavet Paplomata, MD, Principal Investigator, Emory University/Winship Cancer Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.